108 results about "Prolyl Hydroxylases" patented technology

The invention described herein relates to certain bicyclic heteroaromatic N-substituted glycine derivatives of formula (I)

which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

The present invention relates to substituted 4-hydroxypyrimidine-5-carboxamides useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

The invention relates to an oral nutrition composition for beautifying skin, which contains collagen, hyaluronicacid and vitamin C, wherein the collagen is active small molecule peptide with the molecular weight of 2000-6000Dalton, the hyaluronicacid is sodium salt, zinc salt and kali salt, and the vitamin C is natural or synthesized. The invention overcomes the defects that the collagen can not be absorbed by a human body or hydrolyzed into amino acid because the molecular weight is too big, and most of the collagen loses the beautifying efficacy and the like. Hydroxyproline in collagen peptide is promoted to generate by using the vitamin C through active prolyl hydroxylases, the collagen forms big molecule collagen required by beautifying the skin by crosslinked with the hydroxyproline, the hyaluronicacid is also a better nutrient absorption promoting agent except for special water-holding function and is matched with the vitamin C and the collagen for use, which can achieve more ideal effect of promoting the hyaluronicacid to be absorbed.

The invention described herein relates to certain pyridazinedione N-substituted glycine derivatives of formula (I)

which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

The invention discloses a method for producing CIS-4-hydroxyproline. The method comprises the steps of obtaining a recombinant strain by constructing an overexpression prolyl hydroxylase gene Ecp4H in a host bacteria cell and inhibiting expressions of a prolyl hydroxylase gene putA during degradation pathway of proline and succinate dehydrogenase genes sucA and sucB, an isocitrate lyase gene aceA and an isocitrate kinase gene aceK during degradation pathway of alpha-ketoglutaric acid by utilizing a CRISPR-Cas9 technology, and conducting whole-cell transformation and production on the CIS -4- hydroxyproline after conducting fermentation and cultivation on the recombinant strain. The method for the CIS -4- hydroxyproline is simple in cultivation mode and high in strain vigor and product yield.

The present invention provides a triazolopyridine compound having a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability. The present invention relates to a compound represented by the following formula [I]:

wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as a prolyl hydroxylase inhibitor or erythropoietin production-inducing agent containing the compound. The compound of the present invention shows a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability and is useful as a prophylactic or therapeutic agent for various diseases and pathologies (disorders) caused by decreased production of erythropoietin.

The invention described herein relates to certain pyrimidinetrione N-substituted glycine derivatives of formula (I), (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

The invention described herein relates to certain bicyclic heteroaromatic N-substituted glycine derivatives of formula (I)

which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

The invention relates to the field of medicinal chemistry, in particular to a triazopyridine formylglycine compound (I). The compound has high prolyl hydroxylase inhibition activity, and can stabilizeintracellular hypoxia inducing factors, increase generation and secretion of erythropoietin and promote erythropoiesis. The invention also relates to a preparation method of the compound, a medicinalcomposition containing the compound or a pharmaceutically acceptable salt thereof, as well as application of the compound or the pharmaceutically acceptable salt thereof to preparation of medicines for inhibiting prolyl hydroxylase or preparation of medicines for promoting generation of the erythropoietin.

The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond expressed/synthetic to the modulation of PHD2 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short inter-fering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsR-NA), micro-RNA (miRNA), and short hair-pin RNA (shRNA) molecules that are capa-ble of mediating or that mediate RNA inter-ference (RNAi) against PHD2 gene expres-sion.

The present invention relates to spiroazaindole compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

Present invention relates to the Biomarkers for detecting high altitude adaptation and hypoxia responsiveness and the method thereof. The invention specifically relates to the Gene variants SNPIDs rs479200 and rs480902 in the first intron of EGLN1 (Prolyl Hydroxylase 2) gene as biomarkers for adaptation to high altitude and predisposition for high altitude pulmonary edema and hypoxia responsiveness using a novel integrative approach of phenotyping concepts of Ayurveda with population genetics, and disease genomics. More specifically, the C allele of SNP ID rs480902 and T allele of rs479200 of EGLN1 gene is more frequent in patients of HAPE and nearly absent in native highlanders. The present invention also provides primers and methods suitable for the detection of these allelic variants for the prediction of individual's adaptability to high altitude and hypoxia and/or the genetic analysis of the EGLN1 gene in a population.

The invention described herein relates to certain pyrimidinedione N-substituted glycine derivatives of formula (I)

which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.

The invention provides a recombinant humanized III-type collagen. The recombinant humanized III-type collagen has a triple helix structure, and has an amino acid sequence reducing a humanized III-typecollagen alpha-1 chain and including 1068 amino acids. The invention further provides a preparation method of the recombinant humanized III-type collagen, wherein the prolyl hydroxylase of PBCV-1 includes 209 amino acids, and the base sequence is optimized according to the codons of saccharomyces cerevisiae. Compared with the prior art, the preparation method has the advantages that the triple helix is formed in vitro from collagen chains by utilizing the prolyl hydroxylase; and the saccharomyces cerevisiae expression system adopted by the invention is applicable to large-scale amplificationwithout endotoxin or later removal, the preparation cost is low, and the protein expression quantity is further improved. The recombinant humanized III-type collagen is excellent in stability, the amino acid composition of the recombinant humanized III-type collagen is almost completely the same as that of the alpha-1 chain of a natural collagen, and no immunological rejection can be generated when the recombinant humanized III-type collagen is applied to a human body. The recombinant humanized III-type collagen is good in biocompatibility and can be widely applied to surgical treatment and cosmetic medical industry.

The invention provides prolyl hydroxylase and application thereof. The prolyl hydroxylase comprises (a) a protein with an amino acid sequence as shown by SEQ ID NO: 2; (b) a protein with the amino acid sequence as shown by the SEQ ID NO: 2 being mutated through one or more amino acids, and prolyl hydroxylase activity; or (c) a protein with mutation of one or more amino acids in the (b), prolyl hydroxylase activity, and at least 78 percent of homology with the amino acid sequence of the protein in the (b). Due to the protein with the amino acid sequence as shown by the SEQ ID NO: 2 and a mutant obtained through improving the protein by utilizing a gene engineering means, the prolyl hydroxylase provided by the invention has higher catalysis specifity compared with existing prolyl hydroxylase, or the catalytic activity is remarkably improved.

The present invention relates to naphthyridine compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

The invention discloses a new dual inhibitor for prolyl hydroxylase and histone deacetylase shown as formula I, a preparation method and an application thereof. The new dual inhibitor is capable of selectively promoting the level of hypoxia-inducible factor -2alpha(HIF-2alpha) by simultaneously inhibiting activities of prolyl hydroxylase (PHD) and histone deacetylase (HDAC) and is expected to become a new radiation protection drug.

The present invention relates to Tetrahydrofuropyridones compounds useful as HIF prolyl hydroxylase inhibitors to treat anemia and like conditions.

The invention described herein relates to certain bicyclic heteroaromatic N-substituted glycine derivatives of formula (I)

which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.